DoctorWorld.NET: Oncology - Upcoming stories

Insurance Fears Lead Many to Shun DNA Tests - New York Times

nancytice — Sat, 17 May 2008 03:21:10 GMT

Fear of inability to get insurance or withdrawel of insurance keeps people from getting DNA testing

Read more... | Original Medical News | Votes so far: 1 / 0

Cancer doubt remains over mobiles

preity — Sat, 17 May 2008 03:21:10 GMT

The long-term cancer risk of mobile phone use cannot be ruled out, experts have concluded. A major six-year research programme found a "hint" of a higher cancer risk.

Read more... | Original Medical News | Votes so far: 1 / 0

Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Can

preity — Sat, 17 May 2008 03:21:10 GMT

Bilateral orchiectomy or luteinizing hormone–releasing hormone agonists are recommended initial androgen-deprivation treatments (ADTs). Nonsteroidal antiandrogen monotherapy merits discussion as an alternative; steroidal antiandrogen monotherapy should not be offered. Combined androgen blockade should be considered. In metastatic or progressive PCa, immediate versus symptom-onset institution of ADT results in a moderate decrease (17%) in relative risk (RR) for PCa-specific mortality, a moderate increase (15%) in RR for non–PCa-specific mortality, and no overall survival advantage. Therefore, the Panel cannot make a strong recommendation for early ADT initiation. Prostate-specific antigen (PSA) kinetics and other metrics allow identification of populations at high risk for PCa-specific and overall mortality. Further studies must be completed to assess whether patients with adverse prognostic factors gain a survival advantage from immediate ADT. For patients electing to wait until symptoms for ADT, regular monitoring visits are indicated. For patients with recurrence, clinical trials should be considered if available. Currently, data are insufficient to support use of intermittent androgen blockade outside clinical trials.

Read more... | Original Medical News | Votes so far: 2 / 0

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours

graymatter — Sat, 17 May 2008 03:21:10 GMT

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours

Read more... | Original Medical News | Votes so far: 2 / 0

Neuroendocrine Tumors NCCN Clinical Practice Guidelines

graymatter — Sat, 17 May 2008 03:21:10 GMT

Neuroendocrine Tumors NCCN Clinical Practice Guidelines

Read more... | Original Medical News | Votes so far: 2 / 0

Guideline for the Management of Clinically Localized Prostate Cancer

maverick99 — Sat, 17 May 2008 03:21:10 GMT

By the American Urological Association

Read more... | Original Medical News | Votes so far: 2 / 0

American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphos

maverick99 — Sat, 17 May 2008 03:21:10 GMT

To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded the guideline to include a discussion of osteonecrosis of the jaw (ONJ).

Read more... | Original Medical News | Votes so far: 2 / 0

Kidney Cancer - NCCN Clinical Practice Guidelines in Oncology

maverick99 — Sat, 17 May 2008 03:21:10 GMT

Kidney Cancer - NCCN Clinical Practice Guidelines in Oncology

Read more... | Original Medical News | Votes so far: 2 / 0

Multicenter study nets new lung tumor-suppressor gene

graymatter — Sat, 17 May 2008 03:21:10 GMT

Collaborating scientists in Boston and North Carolina have found that a particular gene can block key steps of the lung cancer process in mice. The researchers report in the journal Nature that LKB1 is not only a "tumor-suppressor" gene for non-small cell lung cancer in mice, it also may be more powerful than other, better-known suppressors. The study will be published on the journal's Web site on Aug. 5 and later in a print version. If further research shows LKB1 has a similar effect in human

DoctorWorld.NET: Oncology - Upcoming stories

Insurance Fears Lead Many to Shun DNA Tests - New York Times

Cancer doubt remains over mobiles

Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Can

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours

Neuroendocrine Tumors NCCN Clinical Practice Guidelines

Guideline for the Management of Clinically Localized Prostate Cancer

American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphos

Kidney Cancer - NCCN Clinical Practice Guidelines in Oncology

Multicenter study nets new lung tumor-suppressor gene

Mobile phones and cancer [January 2007; 155-5]